BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37716904)

  • 1. URINE TOXICOLOGY PROFILES OF EMERGENCY DEPARTMENT PATIENTS WITH UNTREATED OPIOID USE DISORDER: A MULTI-SITE VIEW.
    Cowan E; Perrone J; Dziura J; Edelman EJ; Hawk K; Herring A; McCormack R; Murphy A; Phadke M; Fiellin DA; D'Onofrio G
    J Emerg Med; 2023 Oct; 65(4):e357-e365. PubMed ID: 37716904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
    Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
    Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone prescriptions among patients with a substance use disorder and a positive fentanyl urine drug screen presenting to the emergency department.
    Ali SA; Shell J; Harris R; Bedder M
    Harm Reduct J; 2023 Oct; 20(1):144. PubMed ID: 37798673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.
    Bogan C; Jennings L; Haynes L; Barth K; Moreland A; Oros M; Goldsby S; Lane S; Funcell C; Brady K
    J Subst Abuse Treat; 2020 Mar; 112S():73-78. PubMed ID: 32220414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder.
    Gryczynski J; Nichols H; Schwartz RP; Mitchell SG; Hill P; Wireman K
    Drug Alcohol Depend; 2019 Nov; 204():107515. PubMed ID: 31525569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021.
    Friedman J; Shover CL
    Addiction; 2023 Dec; 118(12):2477-2485. PubMed ID: 37705148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES.
    Huo S; Heil J; Salzman MS; Carroll G; Haroz R
    J Emerg Med; 2023 Mar; 64(3):391-396. PubMed ID: 37019500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health Care Utilization of Opioid Overdose Decedents with No Opioid Analgesic Prescription History.
    Abbasi AB; Salisbury-Afshar E; Jovanov D; Berberet C; Arunkumar P; Aks SE; Layden JE; Pho MT
    J Urban Health; 2019 Feb; 96(1):38-48. PubMed ID: 30607879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl: A Review.
    Englander H; Thakrar AP; Bagley SM; Rolley T; Dong K; Hyshka E
    JAMA Intern Med; 2024 Jun; 184(6):691-701. PubMed ID: 38683591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of co-occurring substance use in individuals with opioid use disorder.
    Mahoney JJ; Winstanley EL; Lander LR; Berry JH; Marshalek PJ; Haut MW; Marton JL; Kimble WD; Armistead M; Wen S; Cai Y; Hodder SL
    Addict Behav; 2021 Mar; 114():106752. PubMed ID: 33348147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Unintentional Deaths Among Buprenorphine Users.
    Dai Z; Limen GN; Abate MA; Kraner JC; Mock AR; Smith GS
    J Stud Alcohol Drugs; 2023 Jan; 84(1):171-179. PubMed ID: 36799687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and correlates of fentanyl preferences among people with opioid use disorder.
    Hochstatter KR; Terplan M; Mitchell SG; Schwartz RP; Dusek K; Wireman K; Gryczynski J
    Drug Alcohol Depend; 2022 Nov; 240():109630. PubMed ID: 36152404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substance use patterns, sociodemographics, and health profiles of harm reduction service recipients in Burlington, Vermont.
    Erath TG; LaCroix R; O'Keefe E; Higgins ST; Rawson RA
    Harm Reduct J; 2024 Apr; 21(1):76. PubMed ID: 38580997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
    Socias ME; Wood E; Le Foll B; Lim R; Choi JC; Mok WY; Bruneau J; Rehm J; Wild TC; Bozinoff N; Hassan A; Jutras-Aswad D;
    Addiction; 2022 Oct; 117(10):2662-2672. PubMed ID: 35712892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety.
    Saloner B; Whitley P; Dawson E; Passik S; Gordon AJ; Stein BD
    Addiction; 2023 Aug; 118(8):1549-1556. PubMed ID: 37158468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting.
    Sobel HG; Warrington JS; Francis-Fath S; Crocker AM; Berger CA
    Addict Sci Clin Pract; 2021 Sep; 16(1):59. PubMed ID: 34593036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergency department patients with untreated opioid use disorder: A comparison of those seeking versus not seeking referral to substance use treatment.
    Coupet E; D'Onofrio G; Chawarski M; Edelman EJ; O'Connor PG; Owens P; Martel S; Fiellin DA; Cowan E; Richardson L; Huntley K; Whiteside LK; Lyons MS; Rothman RE; Pantalon M; Hawk K
    Drug Alcohol Depend; 2021 Feb; 219():108428. PubMed ID: 33307301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of fentanyl exposure and knowledge regarding the risk of its use among emergency department patients with active opioid use history at an urban medical center in Baltimore, Maryland.
    Bach H; Jenkins V; Aledhaim A; Moayedi S; Schenkel SM; Kim HK
    Clin Toxicol (Phila); 2020 Jun; 58(6):460-465. PubMed ID: 31475588
    [No Abstract]   [Full Text] [Related]  

  • 19. Quantifying a potential protective effect of buprenorphine on fatality risk during acute fentanyl exposures.
    Dai Z; Abate MA; Winstanley E; Kraner JC; Lundstrom E; Mock AR; Smith GS
    J Subst Use Addict Treat; 2024 Mar; 158():209252. PubMed ID: 38070651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl.
    Carpenter J; Murray BP; Atti S; Moran TP; Yancey A; Morgan B
    J Med Toxicol; 2020 Jan; 16(1):41-48. PubMed ID: 31471760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.